Clinical Trial Update: Gene Therapy for SLC6A1 Neurodevelopmental Disorder [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update shows a gene therapy program for SLC6A1-related neurodevelopmental disorder is in Phase 1/Phase 2 and enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Slc6a1-related Neurodevelopmental Disorder

Snippet

Sponsor: Emily de los Reyes | Conditions: SLC6A1 | Phase 1, Phase 2 | Status: ENROLLING_BY_INVITATION